Nine Masts Capital’s Biogen BIIB Stock Holding History

Nine Masts Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-300	Closed	-$10K	–	263
2017 Q4	$10K	Hold	300	–	–	﹤0.01%	216
2017 Q3	$49K	Hold	300	–	–	0.01%	128
2017 Q2	$264K	Buy	+300	New	+$79.3K	0.03%	103

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Nine Masts Capital's BIIB Position: Q1 2018 in Review

Nine Masts Capital sold out of Biogen (BIIB) in Q1 2018, closing a stake of 31 shares — an estimated $10K sold.

Nine Masts Capital first reported a position in BIIB in Q2 2017 and held it in 3 quarters. The position peaked at $1.81M in Q2 2017. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q1 2018.

Nine Masts Capital reported no remaining Biogen position as of Q1 2018 after selling out during the quarter.
Nine Masts Capital sold 31 Biogen shares in Q1 2018, an estimated $10K.
Nine Masts Capital first reported a position in Biogen in Q2 2017 and held it in 3 quarters.
Nine Masts Capital's Biogen position peaked at $1.81M in Q2 2017.
1,103 funds tracked by Wall St. Rank held Biogen as of Q1 2018.

Based on Nine Masts Capital's 13F filing for Q1 2018, filed 14 May 2018.